SANUWAVE Health, Inc. (NASDAQ: SNWV)

SANUWAVE Health, Inc. operates in the medical device industry, focusing on regenerative medicine through the use of directed energy products. The company specializes in developing and marketing non-invasive ultrasound technology designed to promote tissue repair and regeneration, particularly in the wound care space. SANUWAVE's mission is to improve patient outcomes by offering effective, user-friendly products that reduce wound burden, accelerate healing times, and minimize patient pain. The company's patented technology leverages low-frequency, non-thermal ultrasound to stimulate biological responses that enhance tissue healing, making it a key player in the advanced wound care market.

SANUWAVE generates revenue primarily through the sale of its UltraMIST system and associated consumables. The UltraMIST system is a non-contact, pain-free device that delivers low-frequency ultrasound to target tissues, promoting wound healing and reducing inflammation. This system is used to treat a variety of acute and chronic wounds, including diabetic foot ulcers, venous leg ulcers, split thickness wounds, deep tissue pressure injuries, and surgical wounds. The company's revenue model follows a "razor/razor blade" approach, where customers purchase the UltraMIST system and then regularly buy sterile, single-use applicators for each treatment. In 2025, UltraMIST systems and consumables accounted for approximately 99% of the company's total revenues, highlighting the central role of this product in SANUWAVE's business.

• UltraMIST System: The UltraMIST system is the flagship product of SANUWAVE, designed to deliver low-frequency, non-thermal ultrasound to promote wound healing. This system uses a fluid mist to transmit energy in a non-contact, pain-free manner, penetrating deep into wound beds to reduce inflammation, kill bacteria and biofilms, and increase blood vessel growth. The UltraMIST system is cleared by the FDA for wound healing and debridement and is reimbursed under the Centers for Medicare and Medicaid Services (CMS) category one code 97610. The system is highly portable and used in various healthcare settings, including hospitals, physician offices, wound centers, nursing homes, and skilled nursing facilities. Treatment times typically range from three to 20 minutes, with an average of six minutes. The UltraMIST system is sold through a combination of direct sales representatives, independent distributors, and resellers, primarily in the United States. The company's manufacturing network includes suppliers and contract service providers, with key components sourced from Nortech Systems, Inc. and Dynamic Group. The UltraMIST system is manufactured in accordance with applicable quality standards and regulatory requirements, and the company's facility in Eden Prairie, MN, is FDA-registered and ISO 13485:2016 certified. The UltraMIST system is backed by a robust intellectual property portfolio, including over 60 issued or pending patents worldwide, which cover various aspects of the company's technology. This portfolio provides a competitive advantage and helps protect the company's innovative products from infringement by others. The UltraMIST system is a key driver of SANUWAVE's revenue, with consumables constituting approximately 58% of total revenues in 2025. As of December 31, 2025, there were 1,292 active systems in the field, indicating a strong customer base and ongoing demand for the product. The UltraMIST system is positioned to benefit from trends in wound care, including the transition to evidence-based medicine and the shift towards "care to the edge," where treatment is directed away from hospital settings to increase ease of care and reduce risks of nosocomial infection. The company aims to change the wound care space by bringing cost-effective, easy-to-use technology to market, appealing to patients, physicians, and payors alike. The UltraMIST system is designed to be user and patient-friendly, addressing objections related to treatment duration, difficulty, and pain, thereby expanding access to high-quality wound care. The company seeks to engage with patients and wounds before they become severe, lowering the barrier to seeking treatment and improving overall patient outcomes. The UltraMIST system is part of a broader strategy to move wound care from a transactional mindset to a consultative one, helping practitioners integrate effective wound treatment into their practice flows and patients' lives. The company's goal is to provide the technology that physicians need to deliver the wound care that patients want, ultimately improving patient lives and outcomes.

SANUWAVE operates in a highly competitive advanced wound care market, facing competition from manufacturers of advanced wound dressings, negative pressure wound therapy systems, cellular and tissue-based products, biologic grafts, and energy-based wound treatment technologies. Key competitors include multinational medical device and wound care companies such as Solventum, Smith & Nephew, Molnlycke Health Care, Essity, Coloplast, and Convatec, as well as manufacturers of cellular and tissue-based products like Organogenesis, MiMedx Group, Integra LifeSciences, Vericel, and Kerecis. Additionally, SANUWAVE competes with energy-based wound treatment technologies developed by Arobella Medical and NanoVibronix, and acoustic wave technologies from SoftWave Tissue Regeneration Technologies. The company's competitive advantage lies in the non-contact application, ease of use, and patient tolerability of the UltraMIST system. However, healthcare providers may choose among many treatment alternatives based on clinical protocols, reimbursement considerations, and physician or facility preference. SANUWAVE's products also compete with conventional wound care approaches, including surgical or sharp debridement, standard wound dressings, compression therapy, and other established wound management practices. Competitive factors include clinical outcomes, ease of use, patient comfort, reimbursement coverage, cost, and the availability of supporting clinical evidence.

The UltraMIST system is used by a diverse range of healthcare providers, including doctors, nurses, nurse practitioners, and physical therapists. These professionals administer treatments in various settings, such as hospitals, clinics, and alternate care facilities. The system's portability and ease of use make it suitable for mobile wound care providers serving patient homes. The general customer base for SANUWAVE's products includes healthcare facilities and professionals involved in wound care, with a focus on the United States market. The company's direct sales force and distribution network help reach these customers, ensuring broad adoption and integration of the UltraMIST system into their practice flows and patient treatment plans.